Optimers News and Research

RSS
Aptamer Group opens new facilities to meet the increasing demand for Optimer technology

Aptamer Group opens new facilities to meet the increasing demand for Optimer technology

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.